Location New York, New York, United States Regions Greater New York Area, East Coast, Northeastern US Gender Male
LinkedIn View on LinkedIn
Since December 2024, Marc Feiglin has been Chief Technology Officer at Excelsior Sciences, a New York city based start-up in the field of AI driven drug discovery, where he is responsible for technology and corporate development activities. Marc worked on founding Excelsior while employed as Vice President and Head of Innovative Technologies at
Deerfield Management, the largest US based investment fund purely focused on healthcare with $14b of assets under management. At Deerfield, Marc was part of the venture creation team where he headed efforts relating to acquiring and developing innovative technologies which enable drug discovery. Prior to Deerfield, Marc was Senior Director for External Innovation and Strategy & Corporate Development at Thermo Fisher Scientific, a laboratory supply and biotechnology company, where he led cross-functional efforts to develop new corporate capabilities for external equity investment and partnering in life science tools, analytical technologies, diagnostics, and bioproduction. Prior to Thermo Fisher, Marc held various positions at Merck Group focused on external partnerships and investments across the electronics, life sciences, and pharmaceutical industries including Global Head of Alliance Management & Partnerships for Merck Electronics and as the local of Head Technology Scouting & Partnerships for Life Sciences and electronics in Israel At Tecan Group, an instrument manufacturer focusing on analytical and automation tools for the life sciences and diagnostics industries, Marc held a variety of roles in product development, marketing, strategy, corporate development, and as CTO. While at Tecan, he developed a novel microfluidic technology for which he was awarded two dozen patents and built the technology into an internal start-up focused on point-of-care diagnostics. Marc started his career as an enzymologist researching infectious diseases at Merck Sharp and Dohme (MSD) where he initially became interested in how to leverage innovation to improve early drug discovery. He was an early adopter of automation technologies for early drug discovery and led the development of the initial ANSI standards for the microplate. Marc has lived or worked in six different countries.
